Search Results
Your search for ,aDd matches 922 pages
Showing 551 - 600Immune System Is Shaping the Future of Multiple Myeloma Treatment
From immunomodulatory agents and proteasome inhibitors to steroids, alkylators, and antibodies, recent years have witnessed an explosion of drug approvals for multiple myeloma. The challenge now, said Amrita Krishnan, MD, FACP, is figuring out how to incorporate them all, particularly in the...
‘Out-of-the-Box’ Approach Plus Temozolomide Extends Survival in Glioblastoma
Using a novel approach called tumor-treating fields—which involves the delivery of low-intensity electric fields to the brain by a patient-operated device—along with standard-of-care temozolomide therapy improved overall survival and progression-free survival vs temozolomide alone in patients with...
Prostate-Specific Antigen Testing Rates Appear to Level Off After Recent Drop
Declines in prostate-specific antigen (PSA) testing that came after changes in government screening guidelines have abated in recent years, according to a new study. In JAMA Internal Medicine, American Cancer Society (ACS) investigators led by Stacy A. Fedewa, PhD, wrote that about 1 in 3 men aged...
Accelerating Pediatric Drug Development: Master Protocols May Be a Way to Go
Development of pediatric cancer drugs has long lagged behind adult drug development for two major reasons: The process is more difficult, and childhood cancer is rarer by far than adult cancer. These and other phenomena in pediatric oncology were the subject of a workshop held by the Friends of...
ASCO Selects 2017–2018 Health Policy Fellows
ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017–2018 ASCO Health Policy Fellowship program, now entering its second year. The fellowship, aimed at early career oncologists, provides the skills necessary to monitor and shape the regulatory and ...
Different Subtypes of Acute Myeloid Leukemia Create Both Clinical and Research Challenges
Acute myeloid leukemia (AML) is the most common leukemia in adults. Each year, about 20,000 Americans will be diagnosed with AML, and roughly 10,000 people in this country will die of the disease. AML progresses quickly, and unless treatment begins soon and is effective , the prognosis is grim....
Expert Point of View: Jonathan Ledermann, MD
Invited discussant Jonathan Ledermann, MD, of UCL Cancer Institute, University College London, said the ARIEL2 results for rucaparib (Rubraca) add to the evidence base for PARP (poly ADP-ribose polymerase) inhibition in ovarian cancer established by olaparib (Lynparza). It’s been about 2 years...
An Oncology Care Model: One Institute’s Experience
At this year’s ASCO Quality Care Symposium, Blase N. Polite, MD, MPP, Associate Professor of Medicine at The University of Chicago Medical Center, examined his practice’s experience with the Oncology Care Model, a Centers for Medicare & Medicaid Services test payment and delivery program...
Increased Recognition of Colorectal Cancer in Young Adults, Even Those Aged 20 to 29, as Evidence Continues to Accumulate
The incidence of colorectal cancer continues to increase among young adults, with the sharpest increase among those aged 20 to 29, according to a recent article in the Journal of the National Cancer Institute.1 This trend has been called disturbing and ominous, but the widely reported results of...
Leading Oncology Professional Societies Launch CancerLinQ® Ambassadors Program
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, and the Oncology Nursing Society (ONS) have recently formed the CancerLinQ® Ambassadors Program. This new collaboration is a national practice engagement initiative that will provide on-the-ground support and guidance to CancerLinQ...
CancerLinQ: Big Data for Quality Benchmarking
At this year’s ASCO Quality Care Symposium, CancerLinQ’s Vice President and Medical Director, Robert S. Miller, MD, shed light on CancerLinQ’s current and future value in the oncology community.1 Dr. Miller opened by explaining to the audience that CancerLinQ™ is an instrument for quality...
Gut Bacteria May Enhance, or Hamper, Response to Anti–PD-1 Agents
The microbiome has become an area of intense interest for many health-related reasons. Add to this list the potential for a positive or a negative effect on responsiveness to immunotherapy. Gut microbiota that were more diverse, and that contained an abundance of a particular bacterial species,...
Thoracic 2017: SBRT Offers Curative Option for Patients With Lung Cancer Aged 80 and Older
Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented by Cassidy et al at the 2017 Multidisciplinary Thoracic Cancers Symposium (Abstract...
Value-Based Approaches to the Rising Costs of Cancer Drugs
It’s no secret that cancer drug costs have skyrocketed out of control, with some treatments costing as much as $100,000 to $200,000 per year and even upward. This has put tremendous strain on the U.S. health-care system, while causing financial toxicity and bankruptcy for many patients. Peter B....
Immunotherapy for Head and Neck Cancer: ‘The Fourth Modality Has Arrived’
“This is a big deal. This is going to change all of oncology, not just head and neck cancer,”1 Tanguy Seiwert, MD, remarked following a summary by Jeffrey Sosman, MD, on advances in immunotherapy for treating cancer.2 Dr. Sosman, Director of the Melanoma Program and Clinical Director of Cancer...
An Oncologist’s Straightforward Guide for Women With Breast Cancer
If you Google the search term “breast cancer,” about 155,000,000 results will pop up in .83 seconds. Add to that pamphlets, journal articles, and library shelves bending under the weight of books written about breast cancer. That’s a mind-bending amount of information to parse through for the...
FDA Approves Telotristat Ethyl for Carcinoid Syndrome Diarrhea
On February 28, the U.S. Food and Drug Administration (FDA) approved telotristat ethyl (Xermelo) tablets in combination with somatostatin analog therapy for the treatment of adults with carcinoid syndrome diarrhea that somatostatin analog therapy alone has inadequately controlled. About...
SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers
People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of cancers...
Quality-of-Life Data From KEYNOTE-024: First-Line Pembrolizumab vs Chemotherapy in Advanced NSCLC
When used as first-line therapy for advanced non–small cell lung cancer (NSCLC), pembrolizumab (Keytruda) yields better health-related quality of life than platinum-based chemotherapy, suggest new data from the randomized phase III KEYNOTE-024 trial.1 After 15 weeks of treatment, changes in scores...
ECCO 2017: Some Patients With Early-Stage Breast Cancer May Benefit More From Breast-Conserving Therapy Than Mastectomy
Breast-conserving therapy (breast-conserving surgery combined with radiation therapy) may be superior to mastectomy in certain patients with breast cancer, according to results from the largest study on this topic to date, presented at the 2017 European Cancer Congress (Abstract 4LBA). Although...
SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers
People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of...
Expert Point of View: Steven Vogl, MD
Presentation of the PERTAIN study data by lead author Grazia Arpino, MD, PhD, was met with high interest at the 2016 San Antonio Breast Cancer Symposium. Steven Vogl, MD, of the Bronx, New York, commented, “This is a very complicated study for me, but it seems that at least half your patients got...
Study Suggests No Evidence for Screening Mammography Cutoff Age
An analysis of data from nearly 6 million screening mammograms found no evidence for a clear cutoff age to stop breast cancer screening. Screening mammography among women aged 75 years was associated with higher cancer detection and lower recall rates than among younger women in the study. These...
Exploring Practical Strategies for Cancer Care in Low-Resource Settings
One of the featured “Big Debates” at the 2016 World Cancer Congress in Paris addressed this question: Are scarce resources best applied to prevention rather than treatment? Many experts do not see prevention vs treatment in such stark terms or even as a realistic scenario. It’s a false dichotomy,...
Expert Point of View: Sergio A. Giralt, MD
Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, New York, and the Melvin Berlin Family Chair in Multiple Myeloma, commented on the findings of the StaMINA trial for The ASCO Post. He said the results of the largest randomized U.S....
Seven MD Anderson Faculty Elected Fellows of the American Association for the Advancement of Science
In recognition of wide-ranging contributions to the fields of cancer prevention; patient care; and basic, translational, and clinical research, seven faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of...
Novel Immunotherapy Combinations May Be the Future of Melanoma Treatment
The future treatment of melanoma may rely on combinations of immunotherapy agents beyond the current checkpoint inhibitors, and they are entering clinical trials, according to Jeffrey Weber, MD, PhD, Deputy Director of the Laura and Isaac Perlmutter Cancer Center at New York University Langone...
Dave, Dave, Dave
It was 1983, and I was in my third year as an attending physician at a major East Coast university medical center and just 5 years out of fellowship. As was common at the time, I saw and treated all malignancies except leukemia and gynecologic cancers. In the middle of a typically busy day at the ...
A Lung Cancer Specialist Talks About Value in Cancer Care
Over the past few years, the term value-based cancer care has become integrated into the vernacular of the oncology community. Value is a subjective term, which is defined largely by its clinical setting. However, value in cancer care is evaluated by the multiple stakeholders involved in the...
Plan Ahead for the Holidays With the Conquer Cancer Foundation
Share the message of hope, strength, and a world free from the fear of cancer with greeting cards and eCertificates from the Conquer Cancer Foundation (CCF). In appreciation of your gift, CCF will mail or ship greeting cards, or e-mail eCertificates. Cards and eCertificates feature artwork created ...
A Note of Thanks From the Conquer Cancer Foundation
Dear Friends: Each year, the Conquer Cancer Foundation of ASCO (CCF) Grants and Awards Ceremony is one of the highlights of the ASCO Annual Meeting. While most of the week in Chicago is packed with meetings, events, and presentations, the Grants and Awards Ceremony is a time for everyone to stop,...
Cautious Optimism About Olaratumab in Soft-Tissue Sarcoma
The current plethora of drugs in development for oncology is leading to the testing of novel agents in common as well as rare diseases. Targeted therapies have been a focus of great interest in soft-tissue sarcomas, with testing of a variety of oral tyrosine kinase inhibitors leading to the...
José R. Conejo-Garcia, MD, PhD, Joins Moffitt as Co-Leader of Immunology Program, Chair of Department of Immunology
José R. Conejo-Garcia, MD, PhD, has joined Moffitt Cancer Center as Coleader of the Immunology Program and Chair of the Department of Immunology. The Immunology Program is focused on defining the regulation role of immune checkpoint molecules in tumor immune surveillance and in identifying new...
Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy
What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...
ASCO’s Quality Training Program Shifts to a Regional Setting; Applications Now Open for 2017
On October 17, applications opened for ASCO’s 2017 Quality Training Program. For 2017, the program, which began 3 years ago, is shifting its model of in-person sessions at ASCO headquarters in Alexandria, Virginia, to regional settings. The program is designed to train oncology health-care...
NIH Expands National Precision Medicine Initiative Cohort Program
The National Institutes of Health (NIH) has announced awards to add four regional medical center groups to the national network of health-care provider organizations that will implement the Precision Medicine Initiative Cohort Program. Combined, the new health-care provider organizations will...
Expect Questions About the FDA Discouraging Use of Ovarian Cancer Screening Tests
The release of a U.S. Food and Drug Administration (FDA) Safety Communication “alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests”1 and recommending against using these tests comes not as a result of startling new studies, but from an...
The Medical Profession Has to Become Culturally Sensitive to the Needs of LGBT Cancer Survivors
Despite my breast cancer diagnosis 4 years ago, I feel really lucky. My cancer was detected relatively early, stage IIB, during a routine mammogram screening—a test that many of my lesbian friends skip because they don’t want to deal with a medical system steeped in a heterosexual culture that is...
Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy
What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...
Small Cell Lung Cancer and Immunotherapy: A Change Is Coming, Just Not Front Line (Yet!)
Ever since the immune checkpoint agents arrived, the pace of clinical investigation in oncology has continued to accelerate with an ever-increasing number of trials of single-agent and combination therapies with novel designs that are transforming our drug-development process. However, even in...
Which Factors Influence Radiotherapy for Brain Metastases?
The advent of more effective systemic therapies, which extend patients’ lives, has also resulted in an increasing incidence of brain metastases, for which clinicians must determine appropriate treatment. Whole-brain radiotherapy has been the traditional treatment modality, but stereotactic...
Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients
The Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group has received federal approval to add a quality-of-life research study, Communication and Education in Tumor Profiling (EAQ152), or COMET, to the NCI-MATCH (EAY131) trial, which is ...
Patricia LoRusso, DO, Named Chair of AACR’s Women in Cancer Research
Patricia LoRusso, DO, Professor of Medicine (Medical Oncology) and Associate Director of Innovative Medicine at Yale Cancer Center, has been named Chair of the Women in Cancer Research (WICR) Council of the American Association for Cancer Research (AACR). WICR is a membership group within the AACR ...
An Oncologist Battles a Preventable Epidemic: Cancer of the Cervix
Cervical cancer incidence and mortality rates—perhaps more than any other chronic disease—shine a grim spotlight on global disparities of care. It is one of the most preventable of human malignancies, yet it is the leading cause of cancer deaths in women around the world. It kills 260,000 women...
Routine PET Surveillance Discouraged in Large Cell Lymphoma
There is no role for routine imaging as a means of following patients with large cell lymphoma, according to Bruce D. Cheson, MD, Deputy Chief of Hematology-Oncology and Professor of Medicine at Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC. “Routine...
Oncologist’s Guilt
The best part of my day is hearing that little voice yell, “It’s Momma!” as my son rushes to greet me with a hug. It is humbling, and sometimes terrifying, to realize that I brought a little person into the world who is completely dependent on my husband and me for survival. Few would argue...
Ronald McDonald House New York Names Ruth C. Browne, SD, MPP, MPH, President and Chief Executive Officer
Ronald McDonald House New York has announced that Ruth C. Browne, SD, MPP, MPH, has been selected as President and Chief Executive Officer of the organization. Dr. Browne joins Ronald McDonald House New York from the Arthur Ashe Institute for Urban Health, where she served as CEO since 2004. She...
Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center found in a report published by Chen et al in Cancer...
Hypofractionated Radiotherapy for Localized Prostate Cancer: A New Standard of Care?
For at least the past quarter of a century, radiobiologists and radiation oncologists have debated the role of hypofractionation (fewer total fractions with a higher dose per fraction) for prostate cancer. The debate stems from the unique radiobiology of prostate cancer and the best means to...
Parents May be More Likely to Support HPV Vaccine Requirements for School Entry If States Include Opt-Out Provisions
Parents are more likely to support laws that would make the human papillomavirus (HPV) vaccine mandatory for school entry if their state offers opt-out provisions, according to a study published by Calo et al in Cancer Epidemiology, Biomarkers & Prevention. However, opt-out provisions may...
